{"denoms":[{"counts":[{"groupId":"BG000","value":"29"}],"units":"Participants"}],"groups":[{"description":"Patients receive romidepsin IV over 4 hours on days 1, 8, and 15 and lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity.\n\nromidepsin: Given IV\n\nlenalidomide: Given PO\n\nlaboratory biomarker analysis: Correlative studies","id":"BG000","title":"Treatment (Romidepsin, Lenalidomide)"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"49","upperLimit":"84","value":"75"}]}],"title":"Age at Registration"}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Customized","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"14"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"22"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"4"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"21"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"2"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"I"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"II"},{"measurements":[{"groupId":"BG000","value":"14"}],"title":"III"},{"measurements":[{"groupId":"BG000","value":"13"}],"title":"IV"}]}],"description":"Ann Arbor Staging\n\n* I = Localized disease, single lymph node region or single organ\n* II = Two or more lymph node regions on the same side of diaphragm\n* III = Two or more lymph node regions above and below the diaphragm\n* IV = Widespread disease; multiple organs, with or without lymph node involvement","paramType":"COUNT_OF_PARTICIPANTS","title":"Stage","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"1","upperLimit":"5","value":"3"}]}]}],"description":"The International Prognostic Index (IPI) is a clinical tool developed by oncologists to aid in predicting the prognosis of patients with aggressive non-Hodgkin's lymphoma.\n\nOne point is assigned for each of the following risk factors:\n\n* Age greater than 60 years\n* Stage III or IV disease\n* Elevated serum LDH\n* ECOG/Zubrod performance status of 2, 3, or 4\n* More than 1 extranodal site\n\nThe sum of the points allotted correlates with the following risk groups:\n\n* Low risk (0-1 points)\n* Low-intermediate risk (2 points)\n* High-intermediate risk (3 points)\n* High risk (4-5 points)","dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"International Prognostic Index (IPI) Score","unitOfMeasure":"units on a scale"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"110","upperLimit":"868","value":"224"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Baseline LDH","unitOfMeasure":"U/L"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}],"title":"Adult T-Cell Leukemia/lymphoma"},{"measurements":[{"groupId":"BG000","value":"16"}],"title":"Angioimmunoblastic T-cell Lymphoma"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Enteropathy-type T-cell Lymphoma"},{"measurements":[{"groupId":"BG000","value":"10"}],"title":"Peripheral T-cell Lymphoma, unspecified"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Subtype","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"6"}],"title":"2"},{"measurements":[{"groupId":"BG000","value":"10"}],"title":"3"},{"measurements":[{"groupId":"BG000","value":"11"}],"title":"4"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"5"}]}],"description":"The International Prognostic Index (IPI) is a clinical tool developed by oncologists to aid in predicting the prognosis of patients with aggressive non-Hodgkin's lymphoma.\n\nOne point is assigned for each of the following risk factors:\n\n* Age greater than 60 years\n* Stage III or IV disease\n* Elevated serum LDH\n* ECOG/Zubrod performance status of 2, 3, or 4\n* More than 1 extranodal site\n\nThe sum of the points allotted correlates with the following risk groups:\n\n* Low risk (0-1 points)\n* Low-intermediate risk (2 points)\n* High-intermediate risk (3 points)\n* High risk (4-5 points)","paramType":"COUNT_OF_PARTICIPANTS","title":"International Prognostic Index (IPI) Score - Discrete","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Indeterminate"},{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Negative"},{"measurements":[{"groupId":"BG000","value":"16"}],"title":"Not Done"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"Positive"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Bone Marrow Involvement","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"14"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"7"}],"title":"2"}]}],"description":"ECOG Performance Status\n\n* 0 = Fully active, able to carry on all pre-disease performance without restriction\n* 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work\n* 2 = Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours\n* 3 = Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours\n* 4 = Completely disabled; cannot carry on any selfcare; totally confined to bed or chair\n* 5 = Dead","paramType":"COUNT_OF_PARTICIPANTS","title":"ECOG Performance Status","unitOfMeasure":"Participants"}],"populationDescription":"One patient did not start any study treatment and was statistically withdrawn."}